Endothelin ETA receptor antagonism in cardiovascular disease

European Journal of Pharmacology

Volumn 737, Issue , 2014, Pages 210-213

  Nasser, Suzanne A ^a   El Mas, Mahmoud M ^b  

^a BEIRUT ARAB UNIVERSITY   (Lebanon)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Cardiovascular disease; Endothelin 1

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; AMBRISENTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; AVOSENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; MACITENTAN; SITAXSENTAN; TEZOSENTAN; ZIBOTENTAN; ENDOTHELIN A RECEPTOR;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; CRITICAL LIMB ISCHEMIA; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FLUID RETENTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIVER FUNCTION; NONHUMAN; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; KIDNEY; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN-1; HUMANS; KIDNEY; RECEPTOR, ENDOTHELIN A;

EID: 84903733968     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.05.046     Document Type: Article

References (51)

1. A.V. Agapitov, and W.G. Haynes Role of endothelin in cardiovascular disease J. Renin Angiotensin Aldosterone Syst. 3 2002 1 15 (Pubitemid 34475087)
2. F. Amiri, A. Virdis, M.F. Neves, M. Iglarz, N.G. Seidah, R.M. Touyz, T.L. Reudelhuber, and E.L. Schiffrin Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction Circulation 110 2004 2233 2240 (Pubitemid 39372507)
3. M. Barton Reversal of proteinuric renal disease and the emerging role of endothelin Nat. Clin. Pract. 4 2008 490 501
4. H.R. Black, G.L. Bakris, M.A. Weber, R. Weiss, M.E. Shahawy, R. Marple, G. Tannoury, S. Linas, B.L. Wiens, J.V. Linseman, R. Roden, and M.J. Gerber Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo controlled dose-ranging study J. Clin. Hypertens. (Greenwich) 9 2007 760 769
5. S.L. Bourque, S.T. Davidge, and M.A. Adams The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives Am. J. Physiol. Regul. Integr. Comp. Physiol. 300 2011 R1288 R1295
6. A.R. Chade, N.J. Stewart, and P.R. Peavy Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease Kidney Int. 85 2014 833 844
7. R.N. Channick, G. Simonneau, O. Sitbon, I.M. Robbins, A. Frost, V.F. Tapson, D.B. Badesch, S. Roux, M. Rainisio, F. Bodin, and L.J. Rubin Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123 (Pubitemid 32971843)
8. ClinicalTrials.gov.1 (NCT00303498, Sponsor: Pfizer) A study of sitaxsentan sodium in subjects with diastolic heart failure. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00303498?term=sitaxsentan&rank=4 (accessed March 14, 2014)
9. ClinicalTrials.gov.2 (NCT01890135, Sponsor: University of Virginia) Zibotentan, an endothelin receptor antagonist, patients with intermittent claudication Available at: http://clinicaltrials.gov/ct2/show/NCT01890135?term= zibotentan&rank=16 (accessed March 14, 2014).
10. P.J. Cowburn, J.G.F. Cleland, J.D. McArthur, M.R. MacLean, J.J.V. McMurray, and H.J. Dargie Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure Lancet 352 1998 201 202 (Pubitemid 28327809)
11. A.P. Davenport International union of pharmacology. XXIX. Update on endothelin receptor nomenclature Pharmacol. Rev. 54 2002 219 226 (Pubitemid 34575711)
12. N. Dhaun, J. Goddard, and D.J. Webb The endothelin system and its antagonism in chronic kidney disease J. Am. Soc. Nephrol. 17 2006 943 955
13. N. Dhaun, I.M. MacIntyre, D. Kerr, V. Melville, N.R. Johnston, S. Haughie, J. Goddard, and D.J. Webb Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease Hypertension 57 2011 772 779
14. H.M. El-Gowelli, M.W. Helmy, R.M. Abdel-Halim, and M.M. El-Mas Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ETB receptor cascade Toxicol. Appl. Pharmacol. 275 2014 88 95
15. M.M. El-Mas, M.M. Mohy El-Din, S.M El-gowilly, and F.M. Sharabi Relative roles of endothelial relaxing factors in cyclosporine-induced impairment of cholinergic and β-adrenergic renal vasodilations Eur. J. Pharmacol. 487 2004 149 158 (Pubitemid 38368992)
16. M.M. El-Mas, M.M. Mohy El-Din, S.M. El-gowilly, and F.M. Sharabi Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor-mediated vasorelaxations J. Cardiovasc. Pharmacol. 43 2004 562 573 (Pubitemid 39090023)
17. M.M. El-Mas, M.M. Mohy El-Din, M.M. Helmy, and A.G. Omar Redox imbalances incite the hypertensive, baroreflex, and autonomic effects of cyclosporine in rats Eur. J. Pharmacol. 694 2012 82 88
18. N. Galiè, M.M. Hoeper, J.S. Gibbs, and G. Simonneau Liver toxicity of sitaxentan in pulmonary arterial hypertension Eur. Respir. J. 37 2011 475 476
19. M. Herrera, and J.L. Garvin Endothelin stimulates endothelial nitric oxide synthase expression in the thick ascending limb Am. J. Physiol. 287 2004 F231 F235
20. L. Holzhauser, and R. Zolty Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening Heart Fail. Rev. 2014 (In press)
21. I.S. Hong, H.V. Coe, and L.M. Catanzaro Macitentan for the treatment of pulmonary arterial hypertension Ann. Pharmacother. 48 2014 538 547
22. E.J. Hoorn, S.B. Walsh, J.A. McCormick, R. Zietse, R.J. Unwin, and D.H. Ellison Pathogenesis of calcineurin inhibitor-induced hypertension J. Nephrol. 25 2012 269 275
23. C.C. Juan, Y.W. Shen, Y. Chien, Y.J Lin, S.F. Chang, and L.T. Ho Insulin infusion induces endothelin-1- dependent hypertension in rats Am. J. Physiol. 287 2004 E948 E954
24. M. Kalani The importance of endothelin-1 for microvascular dysfunction in diabetes Vasc. Health Risk Manag. 4 2008 1061 1068
25. M. Kalani, J. Pernow, J. Bragd, and G. Jörneskog Improved peripheral perfusion during endothelin-A receptor blockade in patients with type 2 diabetes and critical limb ischemia Diabetes Care 31 2008 e56
26. R.M. Kedzierski, and M. Yanagisawa Endothelin system: the double-edged sword in health and disease Annu. Rev. Pharmacol. Toxicol. 41 2001 851 876 (Pubitemid 32385909)
27. N.S. Kirkby, P.W. Hadoke, A.J. Bagnall, and D.J. Webb The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br. J. Pharmacol. 153 2008 1105 1119 (Pubitemid 351415492)
28. D.E. Kohan, and D.M. Pollock Endothelin antagonists for diabetic and non-diabetic chronic kidney disease Br. J. Clin. Pharmacol. 76 2013 573 579
29. D.E. Kohan, N.F. Rossi, E.W. Inscho, and D.M. Pollock Regulation of blood pressure and salt homeostasis by endothelin Physiol. Rev. 91 2011 1 77
30. H. Krum, R.J. Viskoper, Y. Lacourciere, M. Budde, and V. Charlon The effect of an endothelinreceptor antagonist, bosentan, on blood pressure in patients with essential hypertension New Engl. J. Med. 338 1998 784 790 (Pubitemid 28135984)
31. R.C. Moorhouse, D.J. Webb, D.C. Kluth, and N. Dhaun Endothelin antagonism and its Role in the treatment of hypertension Curr. Hypertens. Rep. 15 2013 489 496
32. R. Nakov, E. Pfarr, and S. Eberle Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension Am. J. Hypertens. 15 2002 583 589 (Pubitemid 34734804)
33. M. Naruse, A. Tanabe, K. Naruse, C. Adachi, T. Yoshimoto, T. Seki, S. Takagi, T. Imaki, T. Watanabe, and K. Takano Haemodynamic and biochemical effects of endothelin-A- and -B-receptor antagonist TAK-044 in stroke-prone spontaneously hypertensive rats J. Cardiovasc. Pharmacol. 36 2000 S334 S336
34. S.A. Nasser, A.I. Elmallah, R. Sabra, M.M. Khedr, M.M. El-Din, and M.M. El-Mas Blockade of endothelin ETA, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions Eur. J. Pharmacol. 727 2014 52 59
35. J.M. Pearl, S.A. Wellmann, J.L. McNamara, J.P. Lombardi, C.J. Wagner, J.L. Raake, and D.P. Nelson Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function Ann. Thorac. Surg. 68 1999 1714 1721
36. E. Raichlin, A. Prasad, V. Mathew, B. Kent, D.R. Holmes Jr, G.M. Pumper, R.E. Nelson, L.O. Lerman, and A. Lerman Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis Hypertension 52 2008 522 528
37. L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galiè, C.M. Black, A. Keogh, T. Pulido, A. Frost, S. Roux, I. Leconte, M. Landzberg, and G. Simonneau Bosentan therapy for pulmonary arterial hypertension New Engl. J. Med. 346 2002 896 903 (Pubitemid 34984638)
38. M. Settergren, J. Pernow, K. Brismar, G. Jörneskog, and M. Kalani Endothelin-A receptor blockade improves nutritive skin capillary circulation in patients with type 2 diabetes and albuminuria J. Vasc. Res. 45 2008 295 302 (Pubitemid 351793732)
39. L.A. Shimoda, and S.S. Laurie Vascular remodeling in pulmonary hypertension J. Mol. Med. (Berl) 91 2013 297 309
40. K. Taguchi, and Y. Hattori Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension Circ. Res. 112 2013 227 229
41. E. Thorin, and D.J. Webb Endothelium-derived endothelin-1 Pflug. Arch. 459 2010 951 958
42. R.G. Tilton, C.L. Munsch, S.J. Sherwood, S.J. Chen, Y.F. Chen, C. Wu, N. Block, R.A. Dixon, and T.A. Brock Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist Pulm. Pharmacol. Ther. 13 2000 87 97
43. G. Torre-Amione, J.B. Young, W.S. Colucci, B.S. Lewis, C. Pratt, G. Cotter, K. Stangl, U. Elkayam, J.R. Teerlink, A. Frey, M. Rainisio, and I. Kobrin Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure J. Am. Coll. Cardiol. 42 2003 140 147 (Pubitemid 36760775)
44. I. Vanêcková, H.J. Kramer, A. Bäcker, Z. Vernerová, M. Opocensky, and L. Cervenka Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats Hypertension 46 2005 969 974
45. H. Vatter, and V. Seifert Ambrisentan, a non-peptide endothelin receptor antagonist Cardiovasc. Drug Rev. 24 2006 63 76 (Pubitemid 46696785)
46. M.A. Weber, H. Black, G. Bakris, H. Krum, S. Linas, R. Weiss, J.V. Linseman, B.L. Wiens, M.S. Warren, and L.H. Lindholm A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment resistant hypertension: a randomised, double-blind, placebo controlled trial Lancet 374 2009 1423 1431
47. S. Wedgwood, D.M. McMullan, J.M. Bekker, J.R. Fineman, and S.M. Black Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy Circ. Res. 89 2001 357 364 (Pubitemid 34132675)
48. R.R. Wenzel, T. Littke, S. Kuranoff, C. Jürgens, H. Bruck, E. Ritz, T. Philipp, and A. Mitchell Avosentan reduces albumin excretion in diabetics with macroalbuminuria J. Am. Soc. Nephrol. 20 2009 655 664
49. D.J. Williamson, L.L. Wallman, R. Jones, A.M. Keogh, F. Scroope, R. Penny, C. Weber, and P.S. Macdonald Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension Circulation 102 2000 411 418 (Pubitemid 30490679)
50. M. Yu, V. Gopalakrishnan, and J.R. McNeill Role of endothelin and vasopressin in DOCA-salt hypertension Br. J. Pharmacol. 132 2001 1447 1454 (Pubitemid 32281033)
51. Y. Zhou, W.P. Dirksen, J.L. Zweier, and M. Periasamy Endothelin-1-induced responses in isolated mouse vessels: the expression and function of receptor types Am. J. Physiol. Heart Circ. Physiol. 287 2004 H573 H578